课题基金 / 基金详情

Natural Substance Derivative DHNB is A Novel Xanthine Oxidase Inhibitor

Natural Substance Derivative DHNB is A Novel Xanthine Oxidase Inhibitor
天然物质衍生物DHNB是一种新型黄嘌呤氧化酶抑制剂
批准号:
8443691
负责人:
Changyi Chen
金额:
$16.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-04-01 至 2015-03-31

项目摘要

项目成果

Changyi Chen的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):痛风是由高尿酸血症引起的,高尿酸血症是血液中尿酸水平异常高。一般人群的痛风患病率约为3.9%。此外,痛风和高尿酸血症的合并症也在增加,包括代谢综合征、高血压高脂血症、慢性肾病、糖尿病和冠状动脉疾病。嘌呤分解代谢的关键酶是黄嘌呤氧化酶(xanthine oxidase, XO),是治疗高尿酸血症和痛风的主要靶点。目前针对XO的药物包括别嘌呤醇和非布司他,这些药物有许多副作用。临床迫切需要新的、安全有效的药物来治疗这一疾病。最近,我们首次发现天然化合物原儿茶醛(3,4-二羟基-5-硝基苯甲醛)的衍生物3,4-二羟基-5-硝基苯甲醛(DHNB)在体外和体内都是一种有效的XO抑制剂。此外,我们已经证明DHNB对过氧亚硝酸盐和HOCl有很强的清除作用,而别嘌呤醇则没有这种作用。本提案旨在
英文摘要
DESCRIPTION (provided by applicant): Gout is caused by hyperuricemia, which is an abnormally high level of uric acid in the blood. Gout prevalence is about 3.9% for general population. In addition, comorbidities of gout and hyperuricemia are increasing, including metabolic syndrome, hypertension hyperlipidemia, chronic kidney disease, diabetes, and coronary artery disease. The key enzyme involved in purine catabolism is xanthine oxidase (XO), which is the major target for therapeutic treatment of hyperuricemia and gout. Current drugs targeting XO include Allopurinol and Febuxostat, which have many side effects. There is a pressing clinical need for new, safe and effective drugs for this purpose. Recently, we have discovered, for the first time, that 3,4-dihydroxy-5- nitrobenzaldehyde (DHNB), a derivative of the natural compound protocatechuic aldehyde (3,4- dihydroxybenzaldehyde), is a potent XO inhibitor in vitro and in vivo. In addition, we have shown that DHNB has a strong scavenging effect on peroxynitrite and HOCl, while Allopurinol lacks this effect. This proposal is designed to study the efficacy, pharmacokinetics and toxicity of DHNB for hyperuricemia in mice. Specifically, we will determine the therapeutic efficacy of DHNB for XO inhibition and study the pharmacokinetics of DHNB in mice; determine the potential toxicity of DHNB in mice; and determine whether DHNB interacts with the FAD cofactor and/or molybdenum cofactor of XO. The major innovation of the project is the discovery and development of a new, potent, and safe XO inhibitor which can be used clinically to treat and prevent gout and hyperuricemia-associated diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Surgeon Symposium on Genetics and Genomics of Pancreatic Cancer
  • 批准号:
    7408620
  • 项目类别:
  • 资助金额:
    $0.5万
  • 财政年份:
    2008
  • 负责人:
    Changyi Chen
  • 依托单位:
Molecular Surgeon Research Training on Vascular Disease
  • 批准号:
    7343457
  • 项目类别:
  • 资助金额:
    $11.5万
  • 财政年份:
    2008
  • 负责人:
    Changyi Chen
  • 依托单位:
Molecular Surgeon Research Training on Vascular Disease
  • 批准号:
    8316269
  • 项目类别:
  • 资助金额:
    $13.24万
  • 财政年份:
    2008
  • 负责人:
    Changyi Chen
  • 依托单位:
Molecular Surgeon Research Training on Vascular Disease
  • 批准号:
    7902294
  • 项目类别:
  • 资助金额:
    $24.01万
  • 财政年份:
    2008
  • 负责人:
    Changyi Chen
  • 依托单位:
海外基金